title: Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
abstract: Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BRCA1. However, few studies have assessed the association between breast cancer family history and risk of triple-negative breast cancer. We examined the relationship between having a family history of breast cancer in first-degree relatives and risk of triple-negative breast cancer, and risk of two other breast cancer subtypes defined by tumor marker expression. We evaluated data collected by the Breast Cancer Surveillance Consortium from 2,599,946 mammograms on 1,054,466 women, among whom 15% reported a first-degree family history of breast cancer. Using Cox regression in this cohort, we evaluated subtype-specific associations between family history and risk of triple-negative (N = 705), estrogen receptor-positive (ER+, N = 10,026), and hormone receptor-negative/HER2-expressing (ER-/PR-/HER2+, N = 308) breast cancer among women aged 40-84 years. First-degree family history was similarly and significantly associated with an increased risk of all the subtypes [hazard ratio (HR) = 1.73, 95% confidence interval (CI): 1.43-2.09, HR = 1.62, 95% CI: 1.54-1.70, and HR = 1.56, 95% CI: 1.15-2.13, for triple-negative, ER+, and ER-/PR-/HER2+, respectively]. Risk of all the subtypes was most pronounced among women with at least two affected first-degree relatives (versus women with no affected first-degree relatives, HR(triple-negative) = 2.66, 95% CI: 1.66-4.27, HR(ER+) = 2.05, 95% CI: 1.79-2.36, HR(ER)-(/PR)-(/HER2+) = 2.25, 95% CI: 0.99-5.08). Having a first-degree family history of breast cancer was associated with an increased risk of triple-negative breast cancer with a magnitude of association similar to that for the predominant ER+ subtype and ER-/PR-/HER2+ breast cancer.
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M4-B402, PO Box 19024, Seattle, WA 98109-1024, USA. aphipps@fhcrc.org
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Phipps
authors.forename: Diana S M
authors.initials: DS
authors.lastname: Buist
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Malone
authors.forename: William E
authors.initials: WE
authors.lastname: Barlow
authors.forename: Peggy L
authors.initials: PL
authors.lastname: Porter
authors.forename: Karla
authors.initials: K
authors.lastname: Kerlikowske
authors.forename: Christopher I
authors.initials: CI
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics*; D015331:Cohort Studies; D005192:Family Health; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008327:Mammography / Q000379:methods; D008875:Middle Aged; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics; D012306:Risk
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references.citation: AJR Am J Roentgenol. 1997 Oct;169(4):1001-8
references.pmid: 9308451
references.citation: Hum Pathol. 2006 Sep;37(9):1217-26
references.pmid: 16938528
references.citation: Int J Cancer. 1997 May 29;71(5):800-9
references.pmid: 9180149
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Breast Cancer Res Treat. 2009 Jan;113(2):357-70
references.pmid: 18324472
references.citation: Int J Cancer. 2003 Aug 10;106(1):96-102
references.pmid: 12794763
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43
references.pmid: 17372238
references.citation: Lancet. 2001 Oct 27;358(9291):1389-99
references.pmid: 11705483
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1053-60
references.pmid: 14578142
references.citation: Rev Endocr Metab Disord. 2007 Sep;8(3):255-67
references.pmid: 17508290
references.citation: Am J Hum Genet. 1995 Dec;57(6):1457-62
references.pmid: 8533776
references.citation: Clin Med Res. 2009 Jun;7(1-2):4-13
references.pmid: 19574486
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):946-54
references.pmid: 16702375
references.citation: Breast Cancer Res Treat. 2008 May;109(1):123-39
references.pmid: 17578664
references.citation: Int J Cancer. 1997 Sep 4;72(5):735-8
references.pmid: 9311586
references.citation: Am J Epidemiol. 2000 Dec 15;152(12):1154-63
references.pmid: 11130621
references.citation: Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):319-26
references.pmid: 7655325
references.citation: Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52
references.pmid: 18768247
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68
references.pmid: 15466970
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5652-7
references.pmid: 17116942
references.citation: Breast Cancer Res Treat. 2009 Apr;114(3):549-58
references.pmid: 18437558
references.citation: J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
references.pmid: 14519755
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: Breast J. 2009 Nov-Dec;15(6):593-602
references.pmid: 19764994